

## IDO1

**Reactivity:**Human

**Tested applications:**WB

**Recommended Dilution:**WB 1:500 - 1:2000

**Calculated MW:**45kDa

**Observed MW:**Refer to Figures

**Immunogen:**

Recombinant protein of human IDO1

**Storage Buffer:**

Store at -20. Avoid freeze / thaw cycles. Buffer: PBS with 0.02% sodium azide, 50% glycerol, pH7.3.

**Synonym:**

CD107B; IDO; INDO;

**Catalog #:**A1614

**Antibody Type:**

Polyclonal Antibody

**Species:**Rabbit

**Gene ID:**3620

**Isotype:**IgG

**Swiss Prot:**P14902

**Purity:**Affinity purification

For research use only.

**Background:**

INDO/IDO1/indoleamine 2,3-dioxygenase (IDO) is an IFN--inducible enzyme that catalyzes the rate-limiting step of tryptophan degradation (1). IDO is upregulated in many tumors and in dendritic cells in tumor-draining lymph nodes. Elevated tryptophan catabolism in these cells leads to tryptophan starvation of T cells, limiting T cell proliferation and activation (2). Therefore, IDO is considered an immunosuppressive molecule, and research studies have shown that upregulation of IDO is a mechanism of cancer immune evasion (3). The gastrointestinal stromal tumor drug, imatinib, was found to act, in part, by reducing IDO expression, resulting in increased CD8+ T cell activation and induction of apoptosis in regulatory T cells (4). In addition to its enzymatic activity, IDO was recently shown to have signaling capability through an immunoreceptor tyrosine-based inhibitory motif (ITIM) that is phosphorylated by Fyn in response to TGF-. This leads to recruitment of SHP-1 and activation of the noncanonical NF-B pathway (5).

**To place an order, please [Click HERE](#).**